JBS Buys a Beauty Business at 3.5x Leverage — and the Beef Turnaround Finally Lands
The quarter's real news isn't $23 billion of sales: it's a $542 million all-share deal that turns a protein packer into a consumer platform, timed the same week U.S. beef printed positive EBITDA for the first time in two years.
JBS · Earnings Call · 2026-11-10
A stock that has been waiting for permission
JBS has spent a year being told, politely, that the story is not yet investable. The shares are down 10.6% over the trailing 352 days and sit 32.7% below the April 2026 peak of $18.42; the last ninety days are barely a rounding error at +1.7%. That is the tape of a company whose thesis — diversify across proteins and geographies so that no single cattle cycle can kill you — has been intellectually accepted and financially punished. Q3 was the quarter management tried to change the subject. It did so twice. First, with the thing nobody on the call expected: a Brazilian home-and-personal-care company bought at the exact moment leverage was flagged as the constraint. Second — and this is the part that matters for the next twelve months — the U.S. beef business printed a positive adjusted EBITDA after two straight years of losses.Flora: the pivot disguised as a tax trade
On the eve of the call, JBS announced the acquisition of Flora for a $542 million enterprise value — $367 million of equity, paid entirely in JBS treasury Class A shares, plus $175 million of assumed debt. CFO Guilherme Cavalcanti was unusually explicit that the arithmetic, not the strategic romance, is what makes it work: JBS carries roughly $800 million of ICMS/VAT credits it cannot offset against exports and $2.2 billion of tax credit on the balance sheet, and a domestic-facing asset with the same corporate registration can finally consume them. “when we have Flora inside JBS with the same CNPJ, as we call it the same corporate, we can pay Flora's ICMS on the domestic sales with the own credit or the ICMS credits that we have accumulated” — Guilherme Cavalcanti, Chief Financial Officer · 2026-11-10 On 2027 synergies alone the multiple compresses from 7x to under 4.9x; over ten years management values synergies and credit monetization at $422 million. Against Brazilian comparables of 5–10x EBITDA versus international peers at 10–14x, the framing is deliberate: this is a cheap asset bought with paper, and the paper is the point. But the strategic layer is louder than the tax layer, and it is genuinely new for this company. JBS has spent a decade arguing that geographic diversification — Australia, Brazil, the U.S., Europe — is the hedge. Wesley Batista Filho is now arguing for category diversification: nutrition, supplements, B2C shelf space, and the byproduct stream as a health-ingredients business. “we cannot ignore and we need to be very, very much present in all of the nutritional supplements and nutritional part of the business that we think it's a huge value-added part of the business” — Wesley Batista Filho, Chief Executive Officer · 2026-11-10 Cavalcanti reached for the obvious American analogue — Darling's valuation rests largely on ingredients that enhance human health — which tells you where management wants the multiple to go. Note that 93% of Flora's raw material consumption is already supplied by JBS. This is verticalization toward the consumer, not away from the plant.Two years of promises, one of them kept
The U.S. beef print is the rarer event, because it is a promise that came due. For five quarters, Wesley has been explaining the same mechanism: shut Mexican border, no cattle, no spread. In August 2025 he set a clock on it. “I think the worst part of the cycle is going to be right here for the next maybe 3, 4 quarters” — Wesley Mendonca Batista Filho, Executive · 2025-08-15 And in March 2026, on the reopening itself, he refused to forecast: “I hope it opens this year or as soon as possible, but very difficult forecast” — Wesley Mendonça Filho, Head of U.S. Beef or U.S. Beef Business Executive · 2026-03-31. It opened. The Mexican cattle flow is running toward roughly 1 million head annualized — 4–5% of U.S. processing volumes, but closer to 15% of southern-plant capacity, which is where JBS's footprint sits. Combined with the internal merge of fed, regional and case-ready units under one management structure, the U.S. beef business swung positive and Wesley expects Q4 above Q3, a low-single-digit margin in 2027, and roughly two points of further operational capture. The sensitivity is enormous and worth repeating: every 1% of Beef North America margin is about $300 million of EBITDA, against $721 million of cash consumed by that unit year-to-date. That single line item is the difference between a deleveraging story and another year of defensive explanations.What got quieter — and what got worse
The offsetting hole is U.S. Pork, where the language hardened quarter-over-quarter: “we expect that it will continue to be tough, at least through the first half of next year” — Wesley Batista Filho, Chief Executive Officer · 2026-11-10, with hog producing — the profit engine of the last several years — deteriorating fastest. The IFRS-to-U.S. GAAP gap that confused analysts is entirely Biological assets mark-to-market on the live-hog curve: $1.2 billion of adjusted EBITDA under IFRS versus $1.0 billion under U.S. GAAP, with no cash consequence. Glancing at the global keyword board this quarter, hog price ranked among the market's top themes — as a favorable item for other reporters. That is the mirror image of JBS's problem, and a reminder that protein cycles are a zero-sum read on whoever is holding inventory. Three silences are as informative as the disclosures. First, growth CapEx: roughly $500 million is coming out of the 2027 plan, with the $1 billion of maintenance spending untouched — expansion has quietly gone from a top-ranked theme two quarters ago to a deferral exercise. Second, Pilgrim's Pride: management pre-emptively refused all questions given the 82% ownership and pending buyout proposal, so the chicken segment's story is now told by omission. Third, the $800 million Australia equity sale still awaits FIRB, and is now load-bearing in the leverage math.The discipline question
Year-end should land near 3.5–3.55x, with Q4 free cash flow — deferred livestock payments, the Brazil beef built for China's 2027 quota, Seara's European chicken inventory — offsetting the ugly trailing-twelve-month comparison. Then the descent below 3x in 2027. The tension is that JBS chose the bottom of a beef cycle, at 3.54x net leverage against a stated 2–3x target, to make its most consumer-facing acquisition in years — even if the currency was shares and the leverage is technically unchanged. Cavalcanti's defense is that anything of size in future must be paid in stock, and that "we will be focusing really on deleveraging." Investors have heard that before; what they have not heard before is U.S. beef above zero. For a stock 33% off its high, the second fact is worth more than the first.if we have a turnaround in the Beef segment and we end up with an EBITDA between $5.5 billion or $6 billion, we will be below 3x